Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy for Recurrent and Refractory Hematopoietic and Lymphoid Tumors
NCT05619861Unknown
- Sponsor
- Senlang Bio
- Start
- Apr 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in B cell lymphoma, B-cell leukemia (BCL), T-cell leukemia and 1 more, sponsored by Senlang Bio. Primary endpoint: Incidence and severity of adverse events at 24 months. Status: unknown.
02
Conditions
B cell lymphomaB-cell leukemia (BCL)T-cell leukemiamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05619861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619861.